Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 02.02
    2018

    Van Leeuwenhoeck Issues Equity Research Note Highlighting Value of Recent Indivior Strategic Partnership on GABAB PAM

  • 01.08
    2018

    Addex Therapeutics Equity Research Report Update Issued by valuationLAB

  • 01.03
    2018

    Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments

  • 10.18
    2017

    Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share

  • 10.03
    2017

    Addex Therapeutics ADX71441 Program Awarded $5.3 Million Grant from US National Institute on Drug Abuse to Support Human Studies for the Treatment of Cocaine Use Disorder

  • 09.26
    2017

    Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results

  • 09.18
    2017

    Addex Makes Changes to Executive Management

  • 06.23
    2017

    Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting

  • 06.06
    2017

    Addex Annual General Meeting Scheduled for 22 June 2017

  • 05.31
    2017

    Addex Increases Issued Share Capital and Creates Treasury Shares

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics